Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Drug Discovery: Overview01:26

Drug Discovery: Overview

7.2K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.2K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

463
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
463
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

5.9K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
5.9K
Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

2.6K
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
2.6K
Drug-Receptor Bonds01:25

Drug-Receptor Bonds

2.6K
Drug-receptor bonds are formed through various chemical forces when drugs interact with target cells. Covalent bonds, strong and irreversible, are exemplified by DNA-alkylating anticancer agents that inhibit cell division. However, such irreversible drug binding lacks selectivity and can modify the DNA of the surrounding healthy cells. Covalent binding often contributes to tissue toxicity, as seen with chloroform and paracetamol metabolites binding to the liver, causing hepatotoxicity.
In...
2.6K
Drug-Receptor Interactions01:29

Drug-Receptor Interactions

4.7K
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
4.7K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Generative Replica Exchange: A Flow-Based Framework for Accelerating Replica-Exchange Simulations.

Journal of chemical theory and computation·2026
Same author

The Association Between Childhood Maltreatment and Adult Intestinal Disorders: A Three-Level Meta-Analysis.

Trauma, violence & abuse·2026
Same author

Multimodal Drug-Target Affinity Prediction Via FastKAN-Based Hierarchical Fusion of Sequence, Structure, and Tabular Features.

IEEE journal of biomedical and health informatics·2026
Same author

Digital heart initiative: an ecosystem for digital discovery and precision medicine in cardiology.

National science review·2026
Same author

Mechanistic study on hyaluronic acid polysiloxane gel promoting wound repair guided by wet healing theory.

Biomedical materials (Bristol, England)·2026
Same author

IHGCN-PLA: An interpretable heterogeneous graph convolutional network for protein-ligand binding affinity prediction with multimodal interaction fusion.

Journal of biomedical informatics·2026
Same journal

PFASGroups: An Open-Source Framework for Automated Identification, Structural Classification, and Prioritization of Per- and Polyfluoroalkyl Substances.

Journal of chemical information and modeling·2026
Same journal

DeepKbhb: Context-Aware Prediction of Human Lysine β-Hydroxybutyrylation Sites.

Journal of chemical information and modeling·2026
Same journal

HyperDC: A Non-Uniform Hypergraph Framework for Dual- and Higher-Order Drug Combination Recommendation Across Diverse Complex Diseases.

Journal of chemical information and modeling·2026
Same journal

Correction to "AstraMEV (AI-Guided Structural Assembly of Multi-Epitope Vaccines) Against Infectious Bronchitis Virus".

Journal of chemical information and modeling·2026
Same journal

MolPy: A Large Language Model-Friendly Toolkit for Reactive Topology Editing in Polymer Simulations.

Journal of chemical information and modeling·2026
Same journal

Molecular Mechanisms of KIT Receptor Dimerization and Oncogenic Activation Revealed by Multiscale Simulations.

Journal of chemical information and modeling·2026
查看所有相关文章

相关实验视频

Updated: May 17, 2025

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.2K

不同质的图形对比学习与图形扩散用于药物重新定位.

Guishen Wang1, Honghan Chen1, Handan Wang1

  • 1School of Computer Science and Engineering, Changchun University of Technology, North Yuanda Street No. 3000, Changchun 130012, Jilin, China.

Journal of chemical information and modeling
|May 16, 2025
PubMed
概括
此摘要是机器生成的。

HGCL-DR是一种新的图形对比学习框架,通过整合全球和本地特征来增强药物重新定位. 这种方法有效地确定了现有药物的新用途,在验证研究中表现优于目前的方法.

更多相关视频

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
07:51

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

Published on: May 21, 2018

11.6K
A Knowledge Graph Approach to Elucidate the Role of Organellar Pathways in Disease via Biomedical Reports
07:35

A Knowledge Graph Approach to Elucidate the Role of Organellar Pathways in Disease via Biomedical Reports

Published on: October 13, 2023

1.5K

相关实验视频

Last Updated: May 17, 2025

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.2K
High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
07:51

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

Published on: May 21, 2018

11.6K
A Knowledge Graph Approach to Elucidate the Role of Organellar Pathways in Disease via Biomedical Reports
07:35

A Knowledge Graph Approach to Elucidate the Role of Organellar Pathways in Disease via Biomedical Reports

Published on: October 13, 2023

1.5K

科学领域:

  • 计算生物学是一种计算生物学.
  • 药理学 药理学是指药理学的学科.
  • 机器学习是机器学习.

背景情况:

  • 药物重新定位为传统药物开发提供了具有成本效益的替代方案.
  • 准确地建模复杂的药物疾病关系是一个重大挑战.
  • 现有的方法很难有效地捕获本地和全球特征表示.

研究的目的:

  • 引入HGCL-DR,一种新的异质图对比学习框架,用于改进药物重新定位.
  • 有效地整合全球和本地特征表示,以增强药物疾病关系建模.
  • 验证框架的性能和在识别新药候选药物的实际实用性.

主要方法:

  • 开发了一种改进的异质图对比学习方法,用于药物-疾病关系.
  • 采用双向图形卷积网络,用于局部特征提取的子图形生成.
  • 利用图形扩散用于远程依赖和对比学习用于全球特征提取.

主要成果:

  • 在四个基准数据集中,HGCL-DR的表现始终超过了最先进的基线.
  • 在AUPR,AUROC和F1得分指标中取得了卓越的表现.
  • 案例研究表明,在识别阿尔茨海默病和乳腺瘤的潜在候选药物方面具有实际效用.

结论:

  • HGCL-DR是一种有效的计算方法,用于药物重新定位.
  • 该框架成功地整合了全球和本地特征,用于强大的药物疾病建模.
  • 拟议的组件对模型的整体性能和实用性做出了重大贡献.